Drug Type Bispecific antibody |
Synonyms- |
Target |
Mechanism CD20 inhibitors(B-lymphocyte antigen CD20 inhibitors), CD3 inhibitors(T cell surface glycoprotein CD3 inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Chronic Lymphocytic Leukemia | Preclinical | DE | 03 Aug 2024 | |
Diffuse Large B-Cell Lymphoma | Preclinical | DE | 03 Aug 2024 | |
Small Lymphocytic Lymphoma | Preclinical | DE | 03 Aug 2024 |